Telaprevir for previously untreated chronic hepatitis C virus infection

Autor: Jacobson I. M., McHutchison J. G., Dusheiko G., Di Bisceglie A. M., Reddy K. R., Bzowej N. H., Marcellin P., Muir A. J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R. A., Yoshida E. M., Adda N., Bengtsson L., Sankoh A. J., Kieffer T. L., George S., Kauffman R. S., Zeuzem S., ADVANCE Study Team: Gadano A., Terg R., Bell S., Cheng W., Crawford D., Dore G., MacDonald G., Roberts S., Gschwantler M., Laferl H., Maieron A., Heathcote J., Kaita K., Myers R., Sherman M., Yoshida E., Barange K., Couzigou P., Pawlotsky J. M., Pol S., Serfaty L., Trépo C., Zarski J. P., Berg T., Buggisch P., Diepolder H., Goeser T., Mauss S., Rasenack J., Schmidt W., Wedemeyer H., Baruch Y., Ben Ari Z., Maor Y., Safadi R., Zuckerman E., Colombo M., Baka Cwierz B., Gladysz A., Janczewska Kazek E., Jablkowski M., Krycka W., Diago M., Esteban Mur R., Sanchez Tapias J., Brown A., Fox R., Afdhal N., Arora S., Bennett M., Bernstein D., Bloomer J., Bochan M., Bonkovsky H., Brady C., Brown R., Bzowej N., Cochran J., Chasen R., Davis G., De Jesus E., Di Bisceglie A., Dienstag J., Dieterich D., Etzkorn K., Everson G., Fried M., Freilich B., Ghalib R., Gitlin N., Godofsky E., Gordon S., Hassanein T., Jacobson I., Javadi F., Jonas M., Kilby A., Kwo P., Lawitz E., Lebovics E., Lee W., Luketic V., Maillard M., Monto A., Morgan T., Min A., Murphy M., Nelson D., Northup P., Nyberg L., Pockros P., Poordad F., Poulos J., Reddy R., Rodriguez Torres M., Satyanarayana R., Schiff E., Schwartz H., Shaikh O., Sheikh M., Sherman K., Smith J., Strohecker J., Sulkowski M., Szabo G., Te H., Terrault N., Tsai N., Vargas H., Vierling J., Wruble L., Younossi Z., Zein N., ANDREONE, PIETRO

A B S T R AC T Background In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon–ribavirin alone, has shown improved efficacy, with poten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052a883adee96e1a0f587feb78d8287d
http://hdl.handle.net/11585/129215

A Concentration Method for HIV Drug Resistance Testing in Low-Level Viremia Samples.

Autor: Li, Qun^1,2 (AUTHOR), Yu, Fengting^1,2 (AUTHOR), Song, Chuan^1,2,3 (AUTHOR), Zhao, Hongxin^1,2 (AUTHOR), Yan, Liting^1,2 (AUTHOR), Xiao, Qing^1,2 (AUTHOR), Lao, Xiaojie^1,2 (AUTHOR), Yang, Siyuan^1,2 (AUTHOR), Tang, Yunxia^1,2 (AUTHOR), Xiao, Jiang^1,2 (AUTHOR), Zhang, Fujie^1,2 (AUTHOR)

Publikováno v: BioMed Research International. 11/23/2022, Vol. 2022, p1-6. 6p.

Low-level viremia episodes appear to affect the provirus composition of the circulating cellular HIV reservoir during antiretroviral therapy.

Autor: Xiao Sun, Hui Zhang, Xiangchen Kong, Nan Li, Tong Zhang, Minghui An, Haibo Ding, Hong Shang, Xiaoxu Han

Publikováno v: Frontiers in Microbiology; 2024, p1-10, 10p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effect of the Synthetic Peptide LKEKK on Psoriasis.

Autor: Navolotskaya, E. V., Sadovnikov, V. B., Zinchenko, D. V., Murashev, A. N.

Publikováno v: Russian Journal of Bioorganic Chemistry; Nov2023, Vol. 49 Issue 6, p1346-1352, 7p